The Opportunity

The Untapped Opportunity in Membrane Biology

Many validated therapeutic targets remain difficult to address because they are dynamic, multipass membrane proteins whose function depends on their conformation, lipid environment, interacting partners, or assembly state.

Target Classes

Difficult Targets, High Value

GPCRs

G protein-coupled receptors — the largest family of membrane proteins and a major drug target class.

Ion channels

Voltage- and ligand-gated channels implicated in neurological and cardiovascular disease.

Transporters

Solute carriers and ABC transporters with roles in cancer metabolism and drug resistance.

Multiprotein assemblies

Receptor complexes whose function depends on the assembled state rather than individual subunits.

Why These Targets Are Hard

Conventional antibody-discovery technologies face fundamental limitations when applied to complex membrane proteins:

Recombinant systems can produce incorrectly folded proteins.
Existing display formats may not preserve native membrane environments.
Functionally important epitopes can depend on protein conformation or multiprotein assembly.
These limitations can stall antibody discovery against GPCRs, ion channels, transporters, and other complex targets.

Why It Matters

Many of these targets are implicated in oncology, neuroscience, immunology, and rare diseases, yet remain largely inaccessible to conventional antibody-discovery technologies. Unlocking them represents one of the most significant opportunities in modern drug development.

Interested in the Opportunity?

We are actively seeking partners and investors who share our vision for transforming antibody discovery against complex membrane targets.